Galera Therapeutics, a Malvern-based biopharmaceutical firm, has filed to go public on the Nasdaq stock exchange under the ticker symbol of GRTX. The expected offering amount is $86.
The company has raised $150 million of Series C venture funding in a deal led by Clarus Ventures late this past year, putting the company's pre-money valuation at $180 million.
Novartis Venture Fund, Novo Holdings, New Enterprise Associates, Correlation Ventures, HBM Healthcare Investments, Nan Fung Life Sciences, Sofinnova Ventures, Adage Capital Management, RA Capital Advisors, Rock Springs Capital, Tekla Capital Management and Galera Angels also participated in the round.
The clinical stage biopharmaceutical company focuses on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
